Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 18, 2024

BUY
$161.01 - $317.85 $48,303 - $95,355
300 New
300 $94,000
Q3 2022

Oct 25, 2022

BUY
$123.79 - $277.42 $102,126 - $228,871
825 New
825 $185,000
Q1 2021

Apr 26, 2021

SELL
$95.46 - $133.08 $84,959 - $118,441
-890 Closed
0 $0
Q4 2020

Jan 21, 2021

BUY
$75.23 - $109.23 $46,567 - $67,613
619 Added 228.41%
890 $90,000
Q3 2020

Oct 27, 2020

SELL
$71.31 - $109.74 $23,460 - $36,104
-329 Reduced 54.83%
271 $20,000
Q2 2020

Jul 22, 2020

SELL
$62.14 - $117.21 $366,874 - $692,007
-5,904 Reduced 90.77%
600 $66,000
Q1 2020

May 07, 2020

BUY
$60.41 - $115.92 $392,906 - $753,943
6,504 New
6,504 $468,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.